The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

chemomab.com

Founded Year

2011

Stage

Reverse Merger | IPO

Total Raised

$10M

Market Cap

0.03B

Stock Price

3.05

About Chemomab Therapeutics

Chemomab develops chemokine blocking therapies for inflammatory and fibrotic disorders.

Chemomab Therapeutics Headquarter Location

Kiryat Atidim Building 7

Tel Aviv, 6158002,

Israel

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Chemomab Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Chemomab Therapeutics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Chemomab Therapeutics News

07:00 EDT Chemomab Therapeutics to Participate in H.C. Wainwright Global Investment Conference

May 18, 2022

USA - English Share this article Share this article TEL AVIV, Israel, May 18, 2022 /PRNewswire/ --  Chemomab Therapeutics Ltd . (Nasdaq: CMMB ), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that management will participate in the virtual portion of the H.C. Wainwright Global Investment Conference, which will take place May 23-26, 2022. HC Wainwright Global Investment Conference Date:                Webcast available on demand starting at 7:00am ET May 24 – May 26, 2022 Format:            Corporate overview webcast Chemomab is also participating in one-on-one meetings with investors. For more information, visit hcwevents.com/globalconference/ . About Chemomab Therapeutics Ltd. Chemomab is a clinical-stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is currently in Phase 2 trials for primary sclerosing cholangitis and liver fibrosis, with a Phase 2 trial in systemic sclerosis expected to begin in late 2022. Contacts:

Chemomab Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Chemomab Therapeutics Rank

  • When was Chemomab Therapeutics founded?

    Chemomab Therapeutics was founded in 2011.

  • Where is Chemomab Therapeutics's headquarters?

    Chemomab Therapeutics's headquarters is located at Kiryat Atidim, Tel Aviv.

  • What is Chemomab Therapeutics's latest funding round?

    Chemomab Therapeutics's latest funding round is Reverse Merger.

  • How much did Chemomab Therapeutics raise?

    Chemomab Therapeutics raised a total of $10M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.